A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

NCT01184885 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Lymphoid Malignancies (New or Relapsed)
Acute Lymphoblastic Leukemia
Burkitt Lymphoma
Lymphoblastic Lymphoma
Mantle Cell Lymphoma
Adult T-cell Leukemia/Lymphoma

Interventions

DRUG: Hyper-CVAD
DRUG: Sirolimus

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]